Literature DB >> 35070298

Next-generation sequencing as an advanced supplementary tool for the diagnosis of pathogens in lower respiratory tract infections: An observational trial in Xi'an, China.

Jie Shao1, Amira Hassouna2,3, Yaqin Wang1, Ruirui Zhang1, Lifang Zhen1, Ruidan Li1, Mingli Chen1, Chengjie Liu1, Xiangye Wang1, Mingming Zhang1, Peng Wang1, Shenghua Yuan1, Jie Chen4, Jun Lu2,3,4,5,6,7,8.   

Abstract

The application of next-generation sequencing (NGS) in routine clinical analysis is still limited. The significance of NGS in the identification of pathogens of lower respiratory tract infection should be assessed as part of routine clinical bacterial examinations and chest imaging results. In the present study, the alveolar lavage fluid samples of 30 patients (25 males and 5 females, aged 19-92 years old, with a median age of 62) were examined by routine bacterial culture and NGS, and the results of pathogen detection and identification were compared. Chest imaging showed consolidation in all 30 patients (100%), and pleural effusion in 13 of the 30 patients (43.33%). The routine bacterial culture of the lavage solution was only positive in 14 of the 30 patients (46.6%), and negative in 16 patients (53.33%). However, the positive rate of NGS test results of the lavage fluid was 100%. A total of 12 cases (40%) were completely consistent with the routine bacterial culture test, with 56 other pathogens of mixed infection detected, accounting for the short comings of the routine bacterial examination. Although NGS cannot distinguish between live and dead bacteria, it is still a useful detection technology for accurate diagnosis of clinical infectious diseases. It is worthy of adaptation in the clinic for more effective clinical management and treatment of the lower respiratory airway infection in addition to the routine bacterial culture testing. Copyright: © Shao et al.

Entities:  

Keywords:  bacterial culture; bronchoalveolar lavage fluid; diagnosis; next-generation sequencing; pulmonary infection

Year:  2021        PMID: 35070298      PMCID: PMC8764650          DOI: 10.3892/br.2021.1497

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


Introduction

Lower respiratory tract infections (LRTIs) refer to infections that involve the respiratory tract below the level of the larynx, and includes tracheitis, bronchitis, bronchiolitis and bronchopneumonia (1,2). LRTIs are the major cause of pneumonia and bronchiolitis in hospitals worldwide (1). LRTIs cause ~3.5 million deaths, as well as 79 million cases of disabilities annually (2). LRTIs are associated with high overall morbidity and mortality in adults, with increased risk in the elderly compared to young adults (3,4). Children admitted with LRTIs were reported to have severe respiratory disease (5), in addition to suffering respiratory sequelae (6) and having a long recovery period (5). Among acute LRTIs, the major common cause for hospitalization of infants is bronchiolitis (7), whereas pneumonia in adults (mainly >65 years) and children is the most common cause of death, accounting for 3.5 million (6.1%) deaths globally and over 1.05 million (11.3%) in lower income countries (8,9) every year. Identification of causative organisms is essential for definitive diagnosis of infectious diseases, as well as decision making with regard to appropriate management. The gold standard method is the usage of bacterial and fungal cultures; however, it is time-consuming and not suitable for identification of unculturable bacteria. PCR and antigen tests are commonly used for viral detection; however, only a defined set of microorganisms can be examined (10). Although a reliable method of identification, viral isolation is also time-consuming, and is insufficiently sensitive. Performing combinations of these procedures, did not show significantly improved pathogen identification in 34-57% of paediatric patients (10), and in 13-62% of adult patients with pneumonia (11,12). In the case of respiratory infection, diagnosis of specific microorganisms occurs when they are isolated from sterile materials such as bronchoalveolar lavage fluid (BALF) (10,13,14). BALF is more suitable than sputum for identifying pathogens of respiratory infections, as less contamination with oral bacteria is possible during collection from the locus of infection (15). BALF is usually obtained for PCR to detect certain viruses (16,17). It is to be noted that the diagnostic yield of causative pathogens from BALF in lower respiratory tract infections in immunosuppressed children was 28-68% (18). BALF is collected using a safe procedure and with a very low rate of morbidity and mortality (19). Several studies reported that the results for microbiological examination of BALF have led to alterations in the management of infections in 38.7-72.7% of patients (18-20). LRTIs are commonly managed by treatment with antibiotics; however, clinical management of LRTIs is difficult due to antibiotic resistance caused by inappropriate use of antimicrobial agents, leading to increased hospital mortality rates, as well as excessive costs for LRTI patients (21). As the effective selection of antibiotics is considered a considerable challenge for all physicians (22), accurate and early identification of the pathogenic bacteria is crucial for the effective selection and use of antibiotics, and may lead to improvements in the management of patients with LRTIs worldwide. Next-generation sequencing (NGS) has been used to identify causative pathogens in various infectious diseases (23-27). It has been proven to be useful for identification of causative organisms in several diseases, such as encephalitis, hepatitis, bloodstream infection and acute myocarditis (28-31). NGS has already been used to detect pathogens from BALF samples. A recent study detected significant reads of candidate pathogens in 34% of BALF samples collected from patients with infectious as well as non-infectious diseases (32). In another study, NGS was used to detect pathogens in the BALF of patients with respiratory infection, and the results suggest that comprehensive molecular diagnostics, as well as surveillance of pathogens in BALF can be achieved using NGS (15). In the present study, NGS technology was used to evaluate its role in accurate detection and identification of pathogens in the alveolar lavage fluid of patients with lower respiratory tract infection, and the results were compared with those of routine pathogen cultures.

Materials and methods

Patients

The present clinical observational study was approved by Norinco 521 Hospital Ethics Committee (Xi'an, China; approval no. 201901) on 9th of January 2019. Between January 2019 and December 2019 in Norinco 521 Hospital, 30 patients were recruited for this study. All were confirmed to have a pulmonary infection based on the clinical symptoms and signs, blood tests and imaging examination. The patients included 25 males and 5 females (male: female, 5:1). The age range of the patients was 19-92 years old, with a median age of 62.

Equipment and reagents

The following equipment were used: Dynamag TM-2 Magnetic frame (Thermo Fisher Scientific, Inc.), HEMA9600 PCR Instrument (China Haidu Black Horse Medical Instrument Co.), Nextseq 550DX sequencer (Illumina, Inc.), Bioruptor GL-16 Sonication Device (Diagenode SA), 5M high speed refrigerated centrifuge (Shanghai Lu Xiangyi Instrument Co., Ltd.), 2100 Biological analyzer (Agilent Technologies, Inc.) and a Qubit™ 4 Fluorometer Nucleic Acid analyzer (Thermo Fisher Scientific, Inc.). The following reagents were used: QIAamp Cador assay kit (cat. no. 54104; Qiagen GmbH), a nucleic acid concentration assay kit (Qubit™ dsDNA HS kit, 500 Assays; cat. no. Q32854; Thermo Fisher Scientific, Inc.), a library construction kit (Sagene DNA Library kit; cat. no. Cp.000002; Sagene Biotechnology) and an NSQ 500/550 Hi Output KT V2.5 (75 CYS) sequencing kit (cat. no. 20024906; Illumina, Inc.).

Specimen collection

The clinical team was involved in talking the participating patients through the process and obtaining signed consent forms before routine tracheal examination. During the tracheal examination, the front end of the trachea was placed in the tube cavity with the most obvious pulmonary infection; 10 ml normal saline was used for bronchial lavage. Part of the lavage fluid (~3 ml) was sent for routine bacterial culture, and 3 ml of the lavage fluid was placed into a sterile, sealable special freezing-storage tube. After sampling, it was immediately placed in an ice box for preservation, and the whole process was preserved with dry ice and a cold storage chain before testing.

Detection process

Volumes of 1 ml samples were collected from the subjects. In order to improve the efficiency of pathogen detection, the samples were first enriched into small volumes (~200 µl) and centrifuged at 12,000 x g for 10 min at 4˚C. Then the 200 µl enriched solutions were used for nucleic acid extraction and purification using a nucleic acid extraction kit combined with magnetic beads (Sagene, Guangzhou, China) according to the manufacturer's protocol, and the metagenomic library was respectively constructed according to the protocol of the library construction kit, Nextera XT (Illumina, Inc.). According to the manufacturer's protocol, the extracted DNA was broken into ~300 bp fragments different and index sequences were added. The library size and quantification were analyzed using a Qubit 4 system and Agarose (0.8% gel) electrophoresis. After the libraries were mixed with equal amounts of the samples, high-throughput sequencing was performed on an Illumina Nextseq 550 DX sequencing platform (sequencing strategy, SE75), an FDA-approved and CE-IVD-certified sequencer. Sequencing details are listed in Table SI, and the data were obtained for subsequent bioinformatics analysis.

Bioinformatics analysis

SOAPnuke software (https://github.com/BGI-flexlab/SOAPnuke, version 1.6.0) was used to filter the data, including removing the base sequences containing sequencing joints, the base sequences consisting of ‘N’ in abundance, and the base sequences containing low quality bases reads. The filtered data were the pure base sequences. All reads were simulated from, and where relevant, aligned to the human genome (Homo sapiens version: GRCh38) using Bowtie2 (https://sourceforge.net/projects/bowtie-bio/files/bowtie2/2.3.5.1/; version 2.3.5.1). The anthropogenic related base sequence was removed, and pathogenic microorganism database comparison was performed on the remaining base sequences after Sagene biological optimization by BWA (https://sourceforge.net/projects/bio-bwa/files/; version 0.7.15). Appraisal of the quantitative results of pathogenic microorganisms was then performed by the senior technician of Sagene Biology Ltd., followed by the generation of a clinical test report. The patients received all the microbiological testing information. The unique pathogenic microorganism database of Guangzhou Sagene Biology was used. The database uses the NCBI database (fp://ncbi nlm.nih.gov/genomes), the Ensemble database (http://ensemblgenomes.org/), Virus Resource database (Virus get Variation Resource), JGI Fungi Porta (http://genome.jgi.doe.gov) and other authoritative microorganism databases as references. The microbial standard was used for verification and optimization.

Statistical analysis

For general clinical information, the mean ± standard deviation, as well as the numerical range are used to describe the data. Percentages are used to the describe individual microbial detection rates in patients. Routine bacterial culture analyses were performed, and statistical analysis was performed manually by the investigators using a four-table χ2 test. P<0.01 was considered to indicate a statistically significant difference.

Report interpretation

After obtaining credible analysis data, the report was interpreted. According to the pathogenicity of the pathogen, they were divided into three tiers. The interpretation standards were: i) High-level pathogenic pathogens were reported immediately after detection, such as Mycobacterium tuberculosis; ii) If ≥3 medium-level conditional pathogenic bacteria were identified, the result was reported; iii) Low-level conditional pathogenic bacteria/common colonizing bacteria, such as coagulase-negative staphylococcus, were reported as suspected background microorganisms, and were carefully considered in conjunction with other clinical tests. For the rare pathogens that were detected, intracellular bacteria and other special pathogens, it was necessary to review the results of biological information analysis and confirm the experimental process, and then report in combination with the clinical history and clinical communication. The reporting rules referred to high-level pathogens for reporting (33).

Results

Clinical information of patients

The clinical information of the 30 patients is shown in Table I. The results showed 22 out of the 30 patients (66.67%) reported a fever, and the majority of them had cough (23/30, 76.67%) and produced sputum (25/30, 83.33%). A total of 10 patients were complicated with a cerebrovascular disease. All patients had consolidation on chest imaging, and 13 patients had pleural effusion (43.33%). The results of bacterial culture were positive in only 11 patients (36.67%) in routine etiological examination. Fungus was detected in the lavage fluid in 3 patients (10%). Bacterial culture results of the lavage fluid of 16 patients were negative (53.33%).
Table I

General clinicopathological information of the recruited patients.

ParameterResult
Time from onset to hospital stay, days[a] (range)10.71±18.98 (0.5-90)
Length of hospital stay, days[a] (range)14.38±9.65 (5-43)
Patients admitted to the ICU, n3
Anti-infection course of treatment, days[a]13.14±8.56
Antifungal course, days[a]8.59±22.91
Noninvasive ventilatory support, n4
Noninvasive ventilatory support duration, days[a]6.75±4.19
Symptoms, n 
     Fever20
     Temperature[b]24
     Cough23
     Expectorant25
     Chest pain3
     Chest tightness13
     Dyspnea11
Complications, n 
     COPD1
     Bronchiectasis1
     Lung cancer1
     Kidney disease1
     Cerebrovascular disease10
     Diabetes2
     Alzheimer's disease1
Routine blood test[a] 
     White blood cell count, 109/l (range)10.88±5.79 (3.4-30.7)
     Neutrophils, 109/l (range)8.48±6.06 (0.43-29.79)
     Platelets, 109/l (range)214.89±84.4 (82-475)
     C-Reactive protein, mg/l (range)50.39±54.06 (5-200)
     Procalcitonin, ng/ml (range)1.62±6.14 (0.05-33.27)
Blood gas analysis, %[a] 
     PO264.81±19.71 (28.2-99.7)
     PCO235.34±8.14 (22.6-55.3)
     SO2%88.64±12.89 (53.2-97.3)
     pH7.43±0.05 (7.35-7.51)
X-ray film, n 
     Consolidation30
     Consolidation with bronchial signs10
     Consolidation without bronchial signs20
     Hydrothorax phenotype13
     Routine etiology examination of bacterial culture positive11
     Fungal positive3

aMean ± standard deviation;

bwithin a range of 38.5-41˚C.

NGS data availability

The microbial gene sequence data obtained were uploaded to the European Nucleotide Archive (ebi.ac.uk/ena). The primary accession no. is PRJEB46374 and the secondary accession no. is ERP130557. The data is publicly available.

Comparison of bacterial culture and NGS detection results of the lavage solution

The comparison of NGS test results and clinical routine culture results of 30 patients is shown in Table II. The results showed that the routine bacterial culture results of the lavage fluid of 16 of the 30 patients were negative (53.3%), and the remaining 14 were positive (46.6%). Lavage NGS detection showed significantly more positive results than the conventional bacterial culture, with a 100% positive rate. Out of those results, 12 of the 30 patients (40%) had test results that were in complete accordance with the hospital routine bacterial culture results, with 56 mixed infections of pathogenic microorganisms detected. The NGS diagnosis was of great significance to the clinical management of the patients, and all cases were effectively treated to a 100% recovery rate.
Table II

Comparison of the NGS and clinical routine culture results.

 NGS detection results
Serial no.Routine bacterial culture resultsBacteriaSpeciesPercentage (%)Same result as routine cultureSupplement
     1Pseudomonas aeruginosaPseudomonasPseudomonas aeruginosa84.0Y 
     2NegativePseudomonasPseudomonas villosa31.0 Y
  Red aureus generaRed string red cocci13.15 Y
     3Acinetobacter bowman, S. aureus (MRSA)Enterococcus generaExcrement enterococcus38.41 Y
  StaphylococciStaphylococcus epidermidis20.16 Y
  CandidaTropical candida71.84 Y
     4NegativePrevotellaProduces black Prevotella42.91 Y
     5NegativePrevotellaProduces black Prevotella29.15 Y
  RothiaSlimy Roche14.11 Y
     6Pseudomonas aeruginosa, E. coliPorphyromonasPorphyromonas gingiva47.01Y 
  bacteroidesBacteroides forsteri34.13 Y
  candidaCandida albicans25.0 Y
     7NegativeStreptococcusStreptococcus bradycaris10.33 Y
  PrevotellaProduces black Prevotella13.22 Y
  SspergillusSmoke aspergillus93.33 Y
     8NegativeStreptococcusStreptococcus bradycaris16.96 Y
  StreptococcusStreptococcus pneumoniae12.95 Y
     9EnterobacteriaceaeHaemophilusHaemophilus parahaemolyticus16.42Y 
  Streptococcus-17.38 Y
  CandidaTropical Candida12.94 Y
10Pseudomonas aeruginosaGreat coliStriated bacillus67.61YY
  PseudomonasPseudomonas aeruginosa12.39  
11Alkali-producing pseudomonasGreat coliStriated bacillus40.06YY
  PseudomonasPseudomonas aeruginosa48.87  
  CandidaCandida albicans92.5 Y
12NegativeStaphylococciStaphylococcus epidermidis45.31 Y
  Lack of bacterial coloniesDeficient hypotrophic bacteria20.56 Y
  ActinomycetesDental caries actinomycetes18.33 Y
  CandidaTropical candida96.98 Y
13NegativeMora bacteria generaMoraxella Oslo68.51 Y
  PichiaAbnormal Pichia pastoris66.67 Y
14NegativePrevotellaMiddle Prevotella24.19 Y
  PrevotellaProduces black Prevotella14.05 Y
  AspergillusAspergillus tubingen25.0 Y
15NegativeVeronicusDeinococcus suivieron10.06 Y
  CandidaEar candida14.29 Y
  AspergillusAspergillus Niger14.29 Y
16NegativePrevotellaProduces black Prevotella24.61 Y
  PrevotellaMiddle Prevotella14.14 Y
  CandidaCandida albicans73.96 Y
17NegativeTwinobacteriaHemolytic twin cocci12.95 Y
18 E. coli Mr Bush speciesE. coli81.63Y 
19Candida albicansEnterococcus generaExcrement enterococcus93.61 Y
  CandidaCandida albicans85.02 Y
20NegativePrevotellaProduces black Prevotella19.15 Y
  ActinomycetesGrapevine actinomycetes10.41 Y
  Actinomycetes-10.97 Y
21Candida albicansEnterococcus generaExcrement enterococcus79.48YY
  CandidaCandida albicans85.53  
22NegativeStreptococcusStreptococcus pneumoniae11.01 Y
  PrevotellaProduces black Prevotella11.42 Y
23Filamentous fungiMora bacteria generaMoraxella Oslo50.0Y 
  AspergillusSmoke aspergillus87.5 Y
24Serratia liquefaciensUsiformisClostridium nucleatus21.94Y 
  MicromonomonasMicromonomonas13.66 Y
25NegativeMora bacteria generaMoraxella Oslo30.49 Y
26NegativeMora bacteria generaMoraxella Oslo54.37 Y
27Stenotrophomonas maltophiliaOligotrophic monomonasStenotrophomonas maltophilia59.86Y 
  Streptococcus-14.78 Y
  CandidaTropical candida48.72 Y
  CandidaSmooth candida30.77 Y
28NegativeStreptococcusStreptococcus pneumoniae17.05 Y
  CandidaCandida albicans75.0 Y
29Kleber pneumoniae, S. aureus bacteriaStreptococcus-34.74YY
  StaphylococciStaphylococcus aureus27.37  
  CandidaCandida albicans91.48 Y
30Sphingomonas aeruginosaStreptococcusStreptococcus bradycaris18.19Y 
  PseudomonasPseudomonas aeruginosa18.48 Y

NGS, next-generation sequencing.

Discussion

In the present study, the alveolar lavage fluid of 30 patients with a pulmonary infection was tested by routine bacterial culture and NGS, and the results of pathogen detection were compared. All 30 patients showed lung consolidation in the X-ray film (Table I), and tested positive with NGS, whereas the conventional bacterial culture method provided positive results in 14 patients only (46.6%), with the remaining 16 patients (53.3%) being negative. This reflects the serious restrictions of the current diagnostic standards for infectious diseases in the clinic, where only routine bacterial culture is used to determine the infection. In 12 cases, NGS test results were in complete accordance with the bacterial culture results, indicating that in those double positive cases, NGS is compatible to the bacterial culture method. In addition, NGS detected 56 mixed infections of pathogenic microorganism, which had important guiding significance to the clinical diagnosis and treatment, compensating for the deficiency of the conventional bacteriology inspections. The routine bacterial culture method is still important as it can distinguish live bacteria from dead ones (34). However, there are a few possible reasons for the lower microbial detection rates: i) The sampling and transition conditions may cause some of the bacteria to die, thus no detection and ii) antibiotic use before sampling may kill some of the bacteria. The handling errors can be minimised through standardisation of the procedures and increased training for personnel. Antibiotic administration should be avoided before sampling, and if it has been used before sampling, then the use can be noted in the patient's medical history, so that this would be accounted for when analysing the final microbial culture results. Conversely, although NGS cannot distinguish between dead and live bacteria, it is still an important additional tool worth exploring, as it does provide additional information and thorough pathological investigation. The results from the NGS performed in the present study are consistent with the Shaanxi Province local etiology epidemic spectrum (35). These results were in line with the previous literature, confirming that NGS detection can improve the positive rate of pathogen detection and provide guidance for treatment in clinical practice. Li et al (36) performed NGS detection on BALF samples from 32 patients, and the positive detection rate of NGS reached 100%. Compared with the culture method, the diagnostic sensitivity and specificity of NGS were 88.89 and 74.07%, respectively. Cummings et al (37) indicated that for complex microbial specimens, bacterial culture may not be able to identify specific microorganisms, but NGS could detect a wider array of organisms than any other single method alone. A retrospective study aiming to evaluate metagenomic NGS (mNGS) for the clinical diagnosis and prognosis of acute respiratory distress syndrome (ARDS) caused by severe pneumonia, reported that the total positive rate detected by NGS method (91.1%) was significantly higher than that detected by the culture method (62.2%). The researchers concluded that, mNGS is a valuable tool to determine the etiological value of ARDS caused by severe pneumonia, providing more diagnostic evidence that leads to improving diagnostic accuracy and prognosis for this disease (38). An additional advantage of using NGS is that it identifies anaerobic bacteria that are not usually searched for by clinical laboratories (39). Early usage of NGS has proven to positively impact the mortality rate as proven by Zhang et al (38). After adjusting the treatment regimen based on the microbiological test results, the 28-day mortality rate in the NGS group (composed of patients tested using NGS and conventional microbiological tests) was significantly lower than that in the non-NGS group (composed of patients given conventional microbiological tests only). NGS significantly reduced the length of stay in the ICU of immunosuppressed patients, shortened the duration of ventilation and reduced the cost of ICU hospitalization (P<0.05) (38). In a recent study, comparing NGS with traditional pathogen detection methods in the diagnosis of peripheral pulmonary infectious lesions, NGS could detect and identify a large variety of pathogens, with identification of at least one microbial species in 89% of the patients with a pulmonary infection. The accuracy and sensitivity of NGS surpassed those of traditional pathogen detection methods. NGS also detected microbes related to human diseases in 94.5% of samples from patients with pulmonary infection who tested negative when assessed by traditional pathogenic detection methods (40). As NGS is an accurate and complete method for detection of all the DNA information in a sample, it can be applied to the detection of various pathogenic microorganisms, including bacteria, fungi and viruses (41,42). It can quickly diagnose Acinetobacter baumannii infection (43), directly detect and confirm pneumocystis from clinical specimens (44) and has the ability to detect a variety of fungi (45). Chen et al (46) applied NGS technology to diagnose 9 cases of severe parrot fever pneumonia, and the patients were treated in a timely manner. The results of a prospective multicenter study showed that among 329 adults with severe community-acquired pneumonia, the detection rate of NGS was 90.3% (47). Cumming et al (37) indicated that for complex microbial specimens, bacterial culture may not be able to identify specific microorganisms, but NGS could detect a greater variety of organisms than any single method alone. This has also been confirmed in other studies that have shown that NGS is considerably more sensitive in the diagnosis of mixed pulmonary infection than conventional methods (97.2% vs. 13.9%) (40,48,49). Furthermore, NGS has been proposed as an important auxiliary diagnostic method for rare pathogens (50). Currently, the new corona pneumonia is also diagnosed by NGS, which can complement and improve clinical pathogenic diagnosis (51). Therefore, NGS is a good pathogenic monitoring method and is worthy of extended application in clinical settings. For pneumonia patients who are not suitable for bronchoalveolar lavage, the NGS test of tracheal secretions can also provide ideal results (52). A recent study suggested that for bacteria and fungi detection, BALF NGS is more sensitive than blood NGS, whereas blood NGS can identify the pathogens of pneumonia, especially for some viruses (53). It is worth mentioning that NGS enabled complete sequencing of the long SARS-CoV-2 genome (~30,000 nucleotides). NGS has also provided insight into strain origin and viral evolution (54). The extensive application of NGS will provide powerful support in the fight against future public health emergencies. The application of these sequencing techniques could further benefit SARS-CoV-2 diagnostic development and novel therapeutic target discovery, as well as blocking interspecies transmission by identifying intermediate SARS-CoV-2 novel hosts (53). The present study has local significance, providing new information regarding the pathogens present in patients with a lung infection in the Xi'an region. NGS has been used in several studies in Xi'an region for detection of pathogens in various infections. Hu et al (55) used NGS to detect SARS-CoV-2 in eye swabs. Lin et al (56) used NGS and a metagenomic approach to detect and characterize respiratory bacteria in an unexplained pneumonia case in an infant. Yang et al (57) used NGS to accurately diagnose granulomatous amoebic encephalitis caused by Balamuthia mandrillaris in a child. Li et al (58) used NGS along with electromagnetic navigation bronchoscopy to diagnose Mycobacterium chelonae. Xu et al (59) used NGS to characterize lncRNAs in 293T cells after human foamy virus infection. No comprehensive study has been performed to compare the detection of bacteria using NGS and routine culture. To the best of our knowledge, the present study is the first in the region, and may provide valuable initial data for future comparative and/or epidemiological studies. In conclusion, early detection of pathogens can optimize antibiotic selection, and consequently improve survival rates in pulmonary infection. NGS is a new technology that uses high-throughput sequencing to sequence all the DNA in human samples. Subsequent quantitative and bioinformatics analyses of microbial species in the samples can provide a reliable basis for clinical diagnosis and treatment. The results of the present study show the prevalence of respiratory pathogens in Xi'an region and supports the implementation of NGS in clinical routine diagnosis for pathogen identification, especially when the results of routine bacterial cultures are negative. Timely sequencing in addition to routine bacterial culture testing will further assist in improving the accuracy of diagnosis and in administration of a more accurate antibiotic regimen.
  52 in total

Review 1.  Clinical and economic burden of community-acquired pneumonia among adults in Europe.

Authors:  T Welte; A Torres; D Nathwani
Journal:  Thorax       Date:  2010-08-20       Impact factor: 9.139

2.  Unbiased Detection of Respiratory Viruses by Use of RNA Sequencing-Based Metagenomics: a Systematic Comparison to a Commercial PCR Panel.

Authors:  Erin H Graf; Keith E Simmon; Keith D Tardif; Weston Hymas; Steven Flygare; Karen Eilbeck; Mark Yandell; Robert Schlaberg
Journal:  J Clin Microbiol       Date:  2016-01-27       Impact factor: 5.948

3.  Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults.

Authors:  Seema Jain; Wesley H Self; Richard G Wunderink; Sherene Fakhran; Robert Balk; Anna M Bramley; Carrie Reed; Carlos G Grijalva; Evan J Anderson; D Mark Courtney; James D Chappell; Chao Qi; Eric M Hart; Frank Carroll; Christopher Trabue; Helen K Donnelly; Derek J Williams; Yuwei Zhu; Sandra R Arnold; Krow Ampofo; Grant W Waterer; Min Levine; Stephen Lindstrom; Jonas M Winchell; Jacqueline M Katz; Dean Erdman; Eileen Schneider; Lauri A Hicks; Jonathan A McCullers; Andrew T Pavia; Kathryn M Edwards; Lyn Finelli
Journal:  N Engl J Med       Date:  2015-07-14       Impact factor: 91.245

4.  Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015.

Authors: 
Journal:  Lancet Infect Dis       Date:  2017-08-23       Impact factor: 25.071

5.  Microbiological Diagnostic Performance of Metagenomic Next-generation Sequencing When Applied to Clinical Practice.

Authors:  Qing Miao; Yuyan Ma; Qingqing Wang; Jue Pan; Yao Zhang; Wenting Jin; Yumeng Yao; Yi Su; Yingnan Huang; Mengran Wang; Bing Li; Huaying Li; Chunmei Zhou; Chun Li; Maosong Ye; Xiaoling Xu; Yongjun Li; Bijie Hu
Journal:  Clin Infect Dis       Date:  2018-11-13       Impact factor: 9.079

6.  Comprehensive detection of viruses in pediatric patients with acute liver failure using next-generation sequencing.

Authors:  Takako Suzuki; Jun-Ichi Kawada; Yusuke Okuno; Satoshi Hayano; Kazuhiro Horiba; Yuka Torii; Yoshiyuki Takahashi; Syuichiro Umetsu; Tsuyoshi Sogo; Ayano Inui; Yoshinori Ito
Journal:  J Clin Virol       Date:  2017-10-03       Impact factor: 3.168

7.  Identification of potential pathogenic viruses in patients with acute myocarditis using next-generation sequencing.

Authors:  Suguru Takeuchi; Jun-Ichi Kawada; Yusuke Okuno; Kazuhiro Horiba; Takako Suzuki; Yuka Torii; Kazushi Yasuda; Atsushi Numaguchi; Taichi Kato; Yoshiyuki Takahashi; Yoshinori Ito
Journal:  J Med Virol       Date:  2018-08-13       Impact factor: 2.327

Review 8.  Balamuthia mandrillaris-Related Primary Amoebic Encephalitis in China Diagnosed by Next Generation Sequencing and a Review of the Literature.

Authors:  Yinan Yang; Xiaobin Hu; Li Min; Xiangyu Dong; Yuanlin Guan
Journal:  Lab Med       Date:  2020-03-10

9.  Metagenomic Analysis Identified Stenotrophomonas maltophilia Pneumonia in an Infant Suffering From Unexplained Very Severe Pneumonia.

Authors:  Yan Lin; Bao-Xi Wang; Ni-Ni Zhang; Lei Zhang; Zhi-Bo Gao; Jiao Tian; Xun Jiang
Journal:  Front Pediatr       Date:  2019-09-19       Impact factor: 3.418

10.  Application of metagenomic next-generation sequencing for bronchoalveolar lavage diagnostics in critically ill patients.

Authors:  Ying Li; Bing Sun; Xiao Tang; Ya-Lan Liu; Hang-Yong He; Xu-Yan Li; Rui Wang; Fei Guo; Zhao-Hui Tong
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-12-07       Impact factor: 3.267

View more
  1 in total

1.  Clinical evaluation of metagenomic next-generation sequencing for detecting pathogens in bronchoalveolar lavage fluid collected from children with community-acquired pneumonia.

Authors:  Wei Guo; Xiaojian Cui; Qiushi Wang; Yupeng Wei; Yanqing Guo; Tongqiang Zhang; Jianghua Zhan
Journal:  Front Med (Lausanne)       Date:  2022-07-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.